Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to evaluate the overall response rate (ORR) in patients with HER2-positive locally advanced or metastatic breast cancer receiving bevacizumab, trastuzumab and capecitabine as first-line treatment for metastatic disease.
Critère d'inclusion
- HER2-positive locally recurrent or metastatic breast cancer